1st-of-its-kind lebrikizumab study held

eAwazMedicine

INDIANAPOLIS — Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of …

Lilly to expand injectable manufacturing capacity in Germany

eAwazMedicine

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) has announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly’s …